






**Supplemental Table S1.** Stage distribution of patients with NSCLC in NHS Lothian during the three study time periods (A: 2012-2013, Pre-SABR, B: 2014-2016, Introduction of SABR, C: 2017-2019, SABR Established).


Stage	Time Period		
	A	B	C
I	24%	25%	26%
II	8%	9%	8%
III	21%	21%	22%
IV	46%	46%	43%



**Supplemental Figure S1.** Overall survival of patients with stage I NSCLC by A: Age, B: Performance Status, C: Charlson Comorbidity Index.



**Supplemental Figure S2.** Treatment utilisation for all patients with stage I NSCLC by A: Age, B: Performance Status, C: Charlson Comorbidity Index.



**Supplemental Figure S3.** Treatment choice matrix by age and performance status for all patients with stage I NSCLC.

**Supplemental Table S2.** Life table for overall survival of all patients with stage I NSCLC by treatment modality. (see also Figure 1).

Overall Survival (months)	0	20	40	60	80	100	120
<b>Surgery</b>	468	415	312	183	108	43	5
<b>SABR</b>	132	116	63	26	9	-	-
<b>CRRT</b>	182	132	75	32	15	4	-
<b>NRT</b>	361	130	54	25	6	1	1

**Supplemental Table S3: Life tables for** overall survival estimates for all patients with stage I NSCLC, and for each treatment group, by treatment time period, A: All patients, B: No radical therapy, C: Conventional Radical Radiotherapy, D: SABR, E: Any Radical Radiotherapy, F: Surgery. (see also Figure 2).

**A**

Overall Survival (months)	0	20	40	60	80	100	120
<b>A – 2012/13, Pre-SABR</b>	252	158	114	80	62	48	6
<b>B – 2014/16, Introduction of SABR</b>	443	305	217	168	76	-	-
<b>C – 2017/19, SABR Established</b>	448	330	173	18	-	-	-

**B**

Overall Survival (months)	0	20	40	60	80	100	120
<b>A – 2012/13, Pre-SABR</b>	83	24	12	6	1	1	1
<b>B – 2014/16, Introduction of SABR</b>	144	52	25	17	5	-	-
<b>C – 2017/19, SABR Established</b>	134	54	17	2	-	-	-

**C**

Overall Survival (months)	0	20	40	60	80	100	120
<b>A – 2012/13, Pre-SABR</b>	51	33	22	10	7	4	-
<b>B – 2014/16, Introduction of SABR</b>	69	54	35	20	8	-	-
<b>C – 2017/19, SABR Established</b>	62	45	18	2	-	-	-

**D**

Overall Survival (months)	0	20	40	60	80	100	120
<b>A – 2012/13, Pre-SABR</b>	-	-	-	-	-	-	-
<b>B – 2014/16, Introduction of SABR</b>	50	41	29	23	9	-	-
<b>C – 2017/19, SABR Established</b>	82	75	34	3	-	-	-

**E**

Overall Survival (months)	0	20	40	60	80	100	120
<b>A – 2012/13, Pre-SABR</b>	51	33	22	10	7	4	-

<b>B – 2014/16, Introduction of SABR</b>	119	95	47	64	43	17	-
<b>C – 2017/19, SABR Established</b>	144	120	52	5	-	-	-


F

<b>Overall Survival (months)</b>	<b>0</b>	<b>20</b>	<b>40</b>	<b>60</b>	<b>80</b>	<b>100</b>	<b>120</b>
<b>A – 2012/13, Pre-SABR</b>	118	101	80	64	54	43	5
<b>B – 2014/16, Introduction of SABR</b>	180	158	128	108	54	-	-
<b>C – 2017/19, SABR Established</b>	170	156	104	11	-	-	-

**Supplemental Table S4.** Overall survival estimates for all patients with stage I NSCLC, and for each treatment group, by treatment time period (A: 2012-2103, Pre-SABR, B: 2104-2106, Introduction of SABR, C: 2017-2019, SABR Established).

	Time Period	Overall Survival (months) (median (IQR))	HR (95%CI), p
All Patients	A	32.5 (13.0-74.8)	1 (Ref)
	B	38.8 (15.7-not reached)	0.87 (0.72-1.03), 0.112
	C	48.8 (19.0-not reached)	<b>0.85 (0.77-0.94), 0.002</b>
No Radical Therapy	A	12.7 (5.1-29.8)	1 (Ref)
	B	13.9 (5.0-29.3)	0.84 (0.64-1.10), 0.207
	C	13.4 (5.6-31.8)	0.95 (0.83-1.10), 0.513
CRRT	A	29.4 (14.4-57.4)	1 (Ref)
	B	41.9 (23.2-65.5)	0.81 (0.55-1.18), 0.269
	C	39.1 (19.2-55.6)	0.93 (0.74-1.17), 0.517
SABR	A	n/a	1 (Ref)
	B	46.2 (27.9-82.3)	n/a~
	C	not reached (31.9-not reached)	n/a
Any Radiotherapy	A	29.4 (14.4-57.1)	1 (Ref)
	B	42.2 (24.2-78.1)	<b>0.70 (0.49-0.99), 0.045</b>
	C	50.4 (24.6-not reached)	<b>0.75 (0.61-0.91), 0.004</b>
Surgery	A	68.2 (28.5-not reached)	1 (Ref)
	B	87.5 (35.7-not reached)	0.83 (0.60-1.13), 0.238
	C	Not reached (54.7-not reached)	<b>0.69 (0.56-0.86), &lt;0.001</b>

(NRT: No Radical Treatment, CRRT: Conventional Radical Radiotherapy, SABR: Stereotactic Ablative Body Radiotherapy)



**Supplemental Figure S4.** Treatment utilisation for all patients aged 75 years and over with stage I NSCLC by time period.